Description of service
SSI will formulate the candidate antigens with their cationic liposomal adjuvant systems CAF®01 and CAF®09b. Short-term stability testing of the CAF-adjuvanted vaccines and physicochemical characterisation of the vaccines will be carried out.
8-12 weeks per project approx.
The Statens Serum Institut (SSI), Vaccine Development Department and Center of Vaccine Research, Denmark
Ida Svahn Rasmussen, IDSR@ssi.dk
Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b
Services do NOT include
In vivo testing of formulation is NOT included.
Optimised vaccine formulation with T cell inducing adjuvant and vaccine characterisation data.
Sample Requirements - input of users
The user must provide vaccine antigen ready to formulate with adjuvant, either lyophilised or in stable aqueous solution including documentation of physico-chemical properties and analytical methods to detect, quantify and characterise the antigen.
Ida Svahn Rasmussen
Currently not available